UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 94

Sortiert nach

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

Clinical infectious diseases, 2020-09, Vol.71 (6), p.1379-1389

2020

Volltextzugriff (PDF)

HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs

Nature medicine, 2010-04, Vol.16 (4), p.446-451

2010

Volltextzugriff (PDF)

Epigenetic silencing of engineered L1 retrotransposition events in human embryonic carcinoma cells

Nature (London), 2010-08, Vol.466 (7307), p.769-773

2010

Volltextzugriff (PDF)

HIV-1 Nef Disrupts Intracellular Trafficking of Major Histocompatibility Complex Class I, CD4, CD8, and CD28 by Distinct Pathways That Share Common Elements

Journal of Virology, 2011-07, Vol.85 (14), p.6867-6881

2011

Volltextzugriff (PDF)

Dengue activates mTORC2 signaling to counteract apoptosis and maximize viral replication

Frontiers in cellular and infection microbiology, 2022-09, Vol.12, p.979996-979996

2022

Volltextzugriff (PDF)

HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells

Cell host & microbe, 2011-03, Vol.9 (3), p.223-234

2011

Volltextzugriff (PDF)

Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials

Clinical infectious diseases, 2021-10, Vol.73 (8), p.1440-1451

2021

Volltextzugriff (PDF)

Compassionate Use of Remdesivir in Children With Severe COVID-19

Pediatrics (Evanston), 2021-05, Vol.147 (5), p.1

2021

Volltextzugriff (PDF)

Spatial presentation of biological molecules to cells by localized diffusive transfer

Lab on a chip, 2019-06, Vol.19 (12), p.2114-2126

2019

Volltextzugriff (PDF)

HIV-1 neutralizing antibody response and viral genetic diversity characterized with next generation sequencing

Virology (New York, N.Y.), 2015-01, Vol.474, p.34-40

2015

Volltextzugriff (PDF)

A Novel Shiga Toxin 1a-Converting Bacteriophage of Shigella sonnei With Close Relationship to Shiga Toxin 2-Converting Pages of Escherichia coli

Open forum infectious diseases, 2016-04, Vol.3 (2), p.ofw079-ofw079

2016

Volltextzugriff (PDF)

Evaluating the role of CRM1-mediated export for adenovirus gene expression

Virology (New York, N.Y.), 2003-10, Vol.315 (1), p.224-233

2003

Volltextzugriff (PDF)

2088. Real-World Geographic Variations of HIV Diagnosis Rates among Individuals Prescribed and not Prescribed Oral HIV Pre-Exposure Prophylaxis (PrEP) Regimens in the United States

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Volltextzugriff (PDF)

1556. Increase in New HIV Diagnoses Following Decrease in Use of Pre-Exposure Prophylaxis (PrEP) During the COVID-19 Pandemic

Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)

2023

Volltextzugriff (PDF)

855. Persistence on F/TAF versus F/TDF for HIV Pre-Exposure Prophylaxis: A Real-World Evidence Analysis in the United States

Open forum infectious diseases, 2021-12, Vol.8 (Supplement_1), p.S518-S519

2021

Volltextzugriff (PDF)

2059. Estimated Background HIV Diagnosis Rates among People Who Could Benefit from Pre-Exposure Prophylaxis (PrEP) at the Metropolitan Statistical Area (MSA) level in the United States, 2012-2019

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Volltextzugriff (PDF)

995. Safety and Efficacy of F/TAF and F/TDF for PrEP in DISCOVER Participants Taking F/TDF for PrEP at Baseline

Open forum infectious diseases, 2020-12, Vol.7 (Supplement_1), p.S526-S527

2020

Volltextzugriff (PDF)

854. Long-term Outcomes of Participants on F/TAF for Pre-Exposure Prophylaxis: Results for 144 Weeks of Follow-Up in the DISCOVER Trial

Open forum infectious diseases, 2021-12, Vol.8 (Supplement_1), p.S517-S518

2021

Volltextzugriff (PDF)

866. Adherence to F/TDF for PrEP in Dried Blood Spots and HIV Infection Rates: A Pooled Analysis of Global PrEP Studies

Open forum infectious diseases, 2021-12, Vol.8 (Supplement_1), p.S524-S525

2021

Volltextzugriff (PDF)

2079. Comparison of Recency Assays to Estimate HIV Incidence in the SIENA (eStimating hIv incidEnce amoNg Agyw) Study in Uganda

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Volltextzugriff (PDF)

848. Approaches to Optimize Recruitment of Historically Underrepresented Black and Hispanic/LatinX MSM, Transgender, and Gender Non-binary Individuals into the Lenacapavir for PrEP (PURPOSE 2) Trial

Open forum infectious diseases, 2021-12, Vol.8 (Supplement_1), p.S514-S514

2021

Volltextzugriff (PDF)

985. Impact of Age and Medical Comorbidities on Renal Outcomes in the DISCOVER Trial

Open forum infectious diseases, 2020-12, Vol.7 (Supplement_1), p.S521-S521

2020

Volltextzugriff (PDF)

1002. A Daily Single Tablet Regimen (STR) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically-Suppressed Adults Living with HIV and End Stage Renal Disease on Chronic Hemodialysis

Open forum infectious diseases, 2020-12, Vol.7 (Supplement_1), p.S529-S530

2020

Volltextzugriff (PDF)

2490. Longer-Term Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed Adults Living With HIV and End-Stage Renal Disease on Chronic Hemodialysis

Open forum infectious diseases, 2019-10, Vol.6 (Supplement_2), p.S864-S864

2019

Volltextzugriff (PDF)

1288. Bone Safety Outcomes with F/TAF vs. F/TDF for PrEP in the DISCOVER Trial

Open forum infectious diseases, 2019-10, Vol.6 (Supplement_2), p.S464-S464

2019

Volltextzugriff (PDF)

1 – 25 von 94

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(87)
Mit Volltextzugriff
(88)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(63)
Life Sciences & Biomedicine
(50)
Humans
(32)
Male
(19)
Female
(16)
Medicin Och Hälsovetenskap
(12)
Animals
(11)
Science & Technology - Other Topics
(10)
Tosca
(10)
Microbiology
(9)
Tuberous Sclerosis
(9)
Clinical Neurology
(8)
Cohort Studies
(8)
Genetics & Heredity
(8)
Life Sciences
(8)
Multidisciplinary Sciences
(8)
Neurosciences
(8)
Neurosciences & Neurology
(8)
Tuberous Sclerosis Complex
(8)
Adolescent
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs

Epigenetic silencing of engineered L1 retrotransposition events in human embryonic carcinoma cells

HIV-1 Nef Disrupts Intracellular Trafficking of Major Histocompatibility Complex Class I, CD4, CD8, and CD28 by Distinct Pathways That Share Common Elements

Dengue activates mTORC2 signaling to counteract apoptosis and maximize viral replication

HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells

Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials

Compassionate Use of Remdesivir in Children With Severe COVID-19

Spatial presentation of biological molecules to cells by localized diffusive transfer

HIV-1 neutralizing antibody response and viral genetic diversity characterized with next generation sequencing

A Novel Shiga Toxin 1a-Converting Bacteriophage of Shigella sonnei With Close Relationship to Shiga Toxin 2-Converting Pages of Escherichia coli

Evaluating the role of CRM1-mediated export for adenovirus gene expression

2088. Real-World Geographic Variations of HIV Diagnosis Rates among Individuals Prescribed and not Prescribed Oral HIV Pre-Exposure Prophylaxis (PrEP) Regimens in the United States

1556. Increase in New HIV Diagnoses Following Decrease in Use of Pre-Exposure Prophylaxis (PrEP) During the COVID-19 Pandemic

855. Persistence on F/TAF versus F/TDF for HIV Pre-Exposure Prophylaxis: A Real-World Evidence Analysis in the United States

2059. Estimated Background HIV Diagnosis Rates among People Who Could Benefit from Pre-Exposure Prophylaxis (PrEP) at the Metropolitan Statistical Area (MSA) level in the United States, 2012-2019

995. Safety and Efficacy of F/TAF and F/TDF for PrEP in DISCOVER Participants Taking F/TDF for PrEP at Baseline

854. Long-term Outcomes of Participants on F/TAF for Pre-Exposure Prophylaxis: Results for 144 Weeks of Follow-Up in the DISCOVER Trial

866. Adherence to F/TDF for PrEP in Dried Blood Spots and HIV Infection Rates: A Pooled Analysis of Global PrEP Studies

2079. Comparison of Recency Assays to Estimate HIV Incidence in the SIENA (eStimating hIv incidEnce amoNg Agyw) Study in Uganda

848. Approaches to Optimize Recruitment of Historically Underrepresented Black and Hispanic/LatinX MSM, Transgender, and Gender Non-binary Individuals into the Lenacapavir for PrEP (PURPOSE 2) Trial

985. Impact of Age and Medical Comorbidities on Renal Outcomes in the DISCOVER Trial

1002. A Daily Single Tablet Regimen (STR) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically-Suppressed Adults Living with HIV and End Stage Renal Disease on Chronic Hemodialysis

2490. Longer-Term Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed Adults Living With HIV and End-Stage Renal Disease on Chronic Hemodialysis

1288. Bone Safety Outcomes with F/TAF vs. F/TDF for PrEP in the DISCOVER Trial

Suchergebnisse filtern